These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 1461215)
1. [New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?]. Engert A; Gottstein C; Winkler U; Schön G; Amlot P; Thorpe P; Diehl V Med Klin (Munich); 1992 Oct; 87(10):503-9. PubMed ID: 1461215 [TBL] [Abstract][Full Text] [Related]
2. Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins. Engert A; Gottstein C; Winkler U; Amlot P; Pileri S; Diehl V; Thorpe P Leuk Lymphoma; 1994 May; 13(5-6):441-8. PubMed ID: 8069189 [TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice. Engert A; Martin G; Pfreundschuh M; Amlot P; Hsu SM; Diehl V; Thorpe P Cancer Res; 1990 May; 50(10):2929-35. PubMed ID: 1692251 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease. Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfreundschuh M; Diehl V; Thorpe P Cancer Res; 1990 Jan; 50(1):84-8. PubMed ID: 2152774 [TBL] [Abstract][Full Text] [Related]
5. Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice. Engert A; Martin G; Amlot P; Wijdenes J; Diehl V; Thorpe P Int J Cancer; 1991 Sep; 49(3):450-6. PubMed ID: 1917143 [TBL] [Abstract][Full Text] [Related]
6. Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma. Schnell R; Vitetta E; Schindler J; Barth S; Winkler U; Borchmann P; Hansmann ML; Diehl V; Ghetie V; Engert A Leuk Lymphoma; 1998 Aug; 30(5-6):525-37. PubMed ID: 9711915 [TBL] [Abstract][Full Text] [Related]
7. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7. Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092 [TBL] [Abstract][Full Text] [Related]
8. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Schnell R; Staak O; Borchmann P; Schwartz C; Matthey B; Hansen H; Schindler J; Ghetie V; Vitetta ES; Diehl V; Engert A Clin Cancer Res; 2002 Jun; 8(6):1779-86. PubMed ID: 12060617 [TBL] [Abstract][Full Text] [Related]
9. Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins. Winkler U; Gottstein C; Schön G; Kapp U; Wolf J; Hansmann ML; Bohlen H; Thorpe P; Diehl V; Engert A Blood; 1994 Jan; 83(2):466-75. PubMed ID: 8286745 [TBL] [Abstract][Full Text] [Related]
10. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody. Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098 [TBL] [Abstract][Full Text] [Related]
11. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen. Schnell R; Linnartz C; Katouzi AA; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch RM; Lange H; Diehl V; Lemke H Int J Cancer; 1995 Oct; 63(2):238-44. PubMed ID: 7591211 [TBL] [Abstract][Full Text] [Related]
12. Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice. Barth S; Huhn M; Matthey B; Schnell R; Tawadros S; Schinköthe T; Lorenzen J; Diehl V; Engert A Int J Cancer; 2000 Jun; 86(5):718-24. PubMed ID: 10797296 [TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES Cancer Res; 1991 Nov; 51(21):5876-80. PubMed ID: 1933855 [TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Schnell R; Borchmann P; Staak JO; Schindler J; Ghetie V; Vitetta ES; Engert A Ann Oncol; 2003 May; 14(5):729-36. PubMed ID: 12702527 [TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma. Griffin TW; Richardson C; Houston LL; LePage D; Bogden A; Raso V Cancer Res; 1987 Aug; 47(16):4266-70. PubMed ID: 3496960 [TBL] [Abstract][Full Text] [Related]
16. Cocktails of ricin A-chain immunotoxins against different antigens on Hodgkin and Sternberg-Reed cells have superior anti-tumor effects against H-RS cells in vitro and solid Hodgkin tumors in mice. Engert A; Gottstein C; Bohlen H; Winkler U; Schön G; Manske O; Schnell R; Diehl V; Thorpe P Int J Cancer; 1995 Oct; 63(2):304-9. PubMed ID: 7591221 [TBL] [Abstract][Full Text] [Related]
17. Identification of an Mr 70,000 antigen associated with Reed-Sternberg cells and interdigitating reticulum cells. Hsu PL; Hsu SM Cancer Res; 1990 Jan; 50(2):350-7. PubMed ID: 2153049 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of human tumor growth by intraperitoneal immunotoxins in nude mice. Marks A; Ettenson D; Bjorn MJ; Lei M; Baumal R Cancer Res; 1990 Jan; 50(2):288-92. PubMed ID: 2295069 [TBL] [Abstract][Full Text] [Related]
19. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins. Griffin T; Raso V Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454 [TBL] [Abstract][Full Text] [Related]
20. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]